{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:29:04Z","timestamp":1790314144015,"version":"4.1.0"},"reference-count":200,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed\/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0006","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:46:30Z","timestamp":1770644790000},"page":"41-60","source":"Crossref","is-referenced-by-count":10,"title":["Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"24","author":[{"given":"Ranjana H.","family":"Advani","sequence":"first","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste M.","family":"Bello","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil M.","family":"Benitez","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bond","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Chen","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheen","family":"Cherian","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Czader","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina","family":"Dabaja","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Daly","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Frosch","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hansen","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim P.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Kelly","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"McConathy","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morgan","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Niu","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Paul","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rabinovitch","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salavati","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Sano","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spinner","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Yang","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Montgomery","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Stehman","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B2","series-title":"Leukemia","first-page":"1720","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I,  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36:1720\u20131748."},{"key":"B3","series-title":"Blood","first-page":"1229","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo E","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR,  The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229\u20131253."},{"key":"B4","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL,  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: IARC Press; 2017."},{"key":"B5","series-title":"N Engl J Med","first-page":"640","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert A","year":"2010","unstructured":"Engert A, Plutschow A, Eich HT,  Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N Engl J Med 2010;363:640\u2013652."},{"key":"B6","series-title":"N Engl J Med","first-page":"1598","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford J","year":"2015","unstructured":"Radford J, Illidge T, Counsell N,  Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 2015;372:1598\u20131607."},{"key":"B7","series-title":"Blood Adv","first-page":"203","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge TM","year":"2020","unstructured":"Illidge TM, Phillips EH, Counsell N,  Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma. Blood Adv 2020;4:203\u2013206."},{"key":"B8","series-title":"J Clin Oncol","first-page":"1786","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre MPE","year":"2017","unstructured":"Andre MPE, Girinsky T, Federico M,  Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 2017;35:1786\u20131794."},{"key":"B9","series-title":"J Clin Oncol","first-page":"19","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico M","year":"2024","unstructured":"Federico M, Fortpied C, Stepanishyna Y,  Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma. J Clin Oncol 2024;42:19\u201325."},{"key":"B10","series-title":"J Clin Oncol","first-page":"2835","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs M","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C,  Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 2019;37:2835\u20132845."},{"key":"B11","series-title":"Leukemia","first-page":"160","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"38","author":"Fuchs M","year":"2024","unstructured":"Fuchs M, Jacob AS, Kaul H,  Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia 2024;38:160\u2013167."},{"key":"B12","series-title":"Int J Radiat Oncol Biol Phys","first-page":"900","article-title":"Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: relapse analysis of GHSG phase 3 HD16 trial","volume":"111","author":"Baues C","year":"2021","unstructured":"Baues C, Goergen H, Fuchs M,  Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: relapse analysis of GHSG phase 3 HD16 trial. Int J Radiat Oncol Biol Phys 2021;111:900\u2013906."},{"key":"B13","series-title":"Blood","first-page":"1013","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus DJ","year":"2018","unstructured":"Straus DJ, Jung SH, Pitcher B,  CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018;132:1013\u20131021."},{"key":"B14","series-title":"Blood","first-page":"1531","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington SF","year":"2016","unstructured":"Barrington SF, Kirkwood AA, Franceschetto A,  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016;127:1531\u20131538."},{"key":"B15","series-title":"N Engl J Med","first-page":"2419","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson P","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A,  Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 2016;374:2419\u20132429."},{"key":"B16","series-title":"J Clin Oncol","first-page":"13","article-title":"Long-term follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma trial","volume":"42","author":"Luminari S","year":"2024","unstructured":"Luminari S, Fossa A, Trotman J,  Long-term follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma trial. J Clin Oncol 2024;42:13\u201318."},{"key":"B17","series-title":"J Clin Oncol","first-page":"1193","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Brockelmann PJ","year":"2023","unstructured":"Brockelmann PJ, Buhnen I, Meissner J,  Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41:1193\u20131199."},{"key":"B18","series-title":"J Clin Oncol","first-page":"327","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker LM","year":"2023","unstructured":"Fornecker LM, Lazarovici J, Aurer I,  Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol 2023;41:327\u2013335."},{"key":"B19","series-title":"Lancet","first-page":"341","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann P","year":"2024","unstructured":"Borchmann P, Ferdinandus J, Schneider G,  Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 2024;404:341\u2013352."},{"key":"B20","series-title":"Lancet","first-page":"1791","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert A","year":"2012","unstructured":"Engert A, Haverkamp H, Kobe C,  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791\u20131799."},{"key":"B21","series-title":"J Clin Oncol","first-page":"684","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon LI","year":"2013","unstructured":"Gordon LI, Hong F, Fisher RI,  Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684\u2013691."},{"key":"B22","series-title":"N Engl J Med","first-page":"1379","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera AF","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM,  Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med 2024;391:1379\u20131389."},{"key":"B23","series-title":"Blood","first-page":"735","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus DJ","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S,  Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020;135:735\u2013742."},{"key":"B24","series-title":"Lancet Haematol","first-page":"e410","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus DJ","year":"2021","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Connors JM,  Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8:e410\u2013421."},{"key":"B25","series-title":"N Engl J Med","first-page":"310","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell SM","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM,  Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 2022;387:310\u2013320."},{"key":"B26","series-title":"N Engl J Med","first-page":"1478","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos GP","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ,  Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478\u20131484."},{"key":"B27","series-title":"J Clin Oncol","first-page":"1175","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","author":"Merli F","year":"2016","unstructured":"Merli F, Luminari S, Gobbi PG,  Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:1175\u20131181."},{"key":"B28","series-title":"N Engl J Med","first-page":"203","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani S","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A,  ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203\u2013212."},{"key":"B29","series-title":"J Clin Oncol","first-page":"2020","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press OW","year":"2016","unstructured":"Press OW, Li H, Schoder H,  US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 2016;34:2020\u20132027."},{"key":"B30","series-title":"Blood","first-page":"1238","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens DM","year":"2019","unstructured":"Stephens DM, Li H, Schoder H,  Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma. Blood 2019;134:1238\u20131246."},{"key":"B31","series-title":"J Clin Oncol","first-page":"454","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini A","year":"2018","unstructured":"Gallamini A, Tarella C, Viviani S,  Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial. J Clin Oncol 2018;36:454\u2013462."},{"key":"B32","series-title":"Lancet","first-page":"1051","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch DC","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH,  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 1993;341:1051\u20131054."},{"key":"B33","series-title":"Lancet","first-page":"2065","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz N","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M,  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 2002;359:2065\u20132071."},{"key":"B34","series-title":"Br J Haematol","first-page":"645","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz CH","year":"2004","unstructured":"Moskowitz CH, Kewalramani T, Nimer SD,  Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease. Br J Haematol 2004;124:645\u2013652."},{"key":"B35","series-title":"Ann Oncol","first-page":"1312","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi B","year":"2008","unstructured":"Sirohi B, Cunningham D, Powles R,  Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma. Ann Oncol 2008;19:1312\u20131319."},{"key":"B36","series-title":"Bone Marrow Transplant","first-page":"21","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle","volume":"20","author":"Brice P","year":"1997","unstructured":"Brice P, Bouabdallah R, Moreau P,  Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1997;20:21\u201326."},{"key":"B37","series-title":"Blood","first-page":"616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz CH","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD,  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616\u2013623."},{"key":"B38","series-title":"Br J Haematol","first-page":"890","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz CH","year":"2010","unstructured":"Moskowitz CH, Yahalom J, Zelenetz AD,  High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890\u2013897."},{"key":"B39","series-title":"J Clin Oncol","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group","volume":"20","author":"Josting A","year":"2002","unstructured":"Josting A, Franklin J, May M,  New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol 2002;20:221\u2013230."},{"key":"B40","series-title":"Ann Oncol","first-page":"625","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda A","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A,  Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol 2005;16:625\u2013633."},{"key":"B41","series-title":"Biol Blood Marrow Transplant","first-page":"529","article-title":"The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial","volume":"9","author":"Stiff PJ","year":"2003","unstructured":"Stiff PJ, Unger JM, Forman SJ,  The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529\u2013539."},{"key":"B42","series-title":"Biol Blood Marrow Transplant","first-page":"98","article-title":"High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin\u2019s disease: a prognostic model for treatment outcomes","volume":"3","author":"Wheeler C","year":"1997","unstructured":"Wheeler C, Eickhoff C, Elias A,  High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin\u2019s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997;3:98\u2013106."},{"key":"B43","series-title":"Blood","first-page":"801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning SJ","year":"1997","unstructured":"Horning SJ, Chao NJ, Negrin RS,  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801\u2013813."},{"key":"B44","series-title":"Cancer","first-page":"2481","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour E","year":"2007","unstructured":"Jabbour E, Hosing C, Ayers G,  Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma. Cancer 2007;109:2481\u20132489."},{"key":"B45","series-title":"Leuk Lymphoma","first-page":"1668","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova H","year":"2011","unstructured":"Mocikova H, Pytlik R, Markova J,  Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 2011;52:1668\u20131674."},{"key":"B46","series-title":"Biol Blood Marrow Transplant","first-page":"1646","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer JP","year":"2011","unstructured":"Smeltzer JP, Cashen AF, Zhang Q,  Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1646\u20131652."},{"key":"B47","series-title":"Blood","first-page":"1665","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz CH","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD,  Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665\u20131670."},{"key":"B48","series-title":"Ann Oncol","first-page":"167","article-title":"ChlVPP therapy for Hodgkin\u2019s disease: experience of 960 patients","volume":"6","year":"1995","unstructured":"The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin\u2019s disease: experience of 960 patients. Ann Oncol 1995;6:167\u2013172."},{"key":"B49","series-title":"Cancer Invest","first-page":"401","article-title":"Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma","volume":"26","author":"Abali H","year":"2008","unstructured":"Abali H, Ur\u00fcn Y, Oks\u00fczo\u011flu B,  Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26:401\u2013406."},{"key":"B50","series-title":"Ann Oncol","first-page":"593","article-title":"ESHAP is an active regimen for relapsing Hodgkin\u2019s disease","volume":"10","author":"Aparicio J","year":"1999","unstructured":"Aparicio J, Segura A, Garcera S,  ESHAP is an active regimen for relapsing Hodgkin\u2019s disease. Ann Oncol 1999;10:593\u2013595."},{"key":"B51","series-title":"J Clin Oncol","first-page":"396","article-title":"Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease before intensive therapy and autologous bone marrow transplantation","volume":"13","author":"Colwill R","year":"1995","unstructured":"Colwill R, Crump M, Couture F,  Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396\u2013402."},{"key":"B52","series-title":"Ann Oncol","first-page":"1628","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting A","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M,  Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol 2002;13:1628\u20131635."},{"key":"B53","series-title":"Ann Hematol","first-page":"1745","article-title":"ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma","volume":"93","author":"Labrador J","year":"2014","unstructured":"Labrador J, Cabrero-Calvo M, Perez-Lopez E,  ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma. Ann Hematol 2014;93:1745\u20131753."},{"key":"B54","series-title":"Br J Haematol","first-page":"161","article-title":"Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease","volume":"113","author":"Martin A","year":"2001","unstructured":"Martin A, Fernandez-Jimenez MC, Caballero MD,  Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease. Br J Haematol 2001;113:161\u2013171."},{"key":"B55","series-title":"Cancer Chemother Pharmacol","first-page":"161","article-title":"VIM-D salvage chemotherapy in Hodgkin\u2019s disease","volume":"27","author":"Phillips JK","year":"1990","unstructured":"Phillips JK, Spearing RL, Davies JM,  VIM-D salvage chemotherapy in Hodgkin\u2019s disease. Cancer Chemother Pharmacol 1990;27:161\u2013163."},{"key":"B56","series-title":"Ann Oncol","first-page":"609","article-title":"A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas","volume":"6","author":"Rodriguez MA","year":"1995","unstructured":"Rodriguez MA, Cabanillas FC, Hagemeister FB,  A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609\u2013611."},{"key":"B57","series-title":"Ann Oncol","first-page":"1071","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett NL","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL,  Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071\u20131079."},{"key":"B58","series-title":"Haematologica","first-page":"35","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro A","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M,  Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica 2007;92:35\u201341."},{"key":"B59","series-title":"J Clin Oncol","first-page":"3490","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump M","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S,  Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490\u20133496."},{"key":"B60","series-title":"Leuk Lymphoma","first-page":"1523","article-title":"Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium","volume":"51","author":"Gopal AK","year":"2010","unstructured":"Gopal AK, Press OW, Shustov AR,  Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523\u20131529."},{"key":"B61","series-title":"Onco Targets Ther","first-page":"2093","article-title":"Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma","volume":"7","author":"Gutierrez A","year":"2014","unstructured":"Gutierrez A, Rodriguez J, Martinez-Serra J,  Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther 2014;7:2093\u20132100."},{"key":"B62","series-title":"J Clin Oncol","first-page":"456","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz AJ","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA, Perales MA,  Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456\u2013460."},{"key":"B63","series-title":"Blood","first-page":"5119","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger TA","year":"2011","unstructured":"Fehniger TA, Larson S, Trinkaus K,  A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119\u20135125."},{"key":"B64","series-title":"Am J Hematol","first-page":"320","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston PB","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP,  A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320\u2013324."},{"key":"B65","series-title":"J Clin Oncol","first-page":"3293","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro A","year":"2016","unstructured":"Santoro A, Mazza R, Pulsoni A,  Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol 2016;34:3293\u20133299."},{"key":"B66","series-title":"Br J Haematol","first-page":"601","article-title":"Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial","volume":"183","author":"Budde LE","year":"2018","unstructured":"Budde LE, Wu D, Martin DB,  Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial. Br J Haematol 2018;183:601\u2013607."},{"key":"B67","series-title":"J Clin Oncol","first-page":"2183","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes A","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE,  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 2012;30:2183\u20132189."},{"key":"B68","series-title":"Blood","first-page":"1236","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal AK","year":"2015","unstructured":"Gopal AK, Chen R, Smith SE,  Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125:1236\u20131243."},{"key":"B69","series-title":"Leuk Lymphoma","first-page":"3320","article-title":"Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"62","author":"Plattel WJ","year":"2021","unstructured":"Plattel WJ, Bergamasco A, Trinchese F,  Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 2021;62:3320\u20133332."},{"key":"B70","series-title":"Lancet Oncol","first-page":"284","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz AJ","year":"2015","unstructured":"Moskowitz AJ, Schoder H, Yahalom J,  PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16:284\u2013292."},{"key":"B71","series-title":"Blood","first-page":"40","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce AS","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A,  Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018;132:40\u201348."},{"key":"B72","series-title":"Lancet Oncol","first-page":"257","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1\u20132 trial","volume":"19","author":"O\u2019Connor OA","year":"2018","unstructured":"O\u2019Connor OA, Lue JK, Sawas A,  Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1\u20132 trial. Lancet Oncol 2018;19:257\u2013266."},{"key":"B73","series-title":"Biol Blood Marrow Transplant","first-page":"2136","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen R","year":"2015","unstructured":"Chen R, Palmer JM, Martin P,  Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2015;21:2136\u20132140."},{"key":"B74","series-title":"Lancet","first-page":"1853","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz CH","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T,  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853\u20131862."},{"key":"B75","series-title":"Blood","first-page":"2639","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz CH","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A,  Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018;132:2639\u20132642."},{"key":"B76","series-title":"N Engl J Med","first-page":"311","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell SM","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I,  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 2015;372:311\u2013319."},{"key":"B77","series-title":"Lancet Oncol","first-page":"1283","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes A","year":"2016","unstructured":"Younes A, Santoro A, Shipp M,  Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283\u20131294."},{"key":"B78","series-title":"J Clin Oncol","first-page":"1428","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand P","year":"2018","unstructured":"Armand P, Engert A, Younes A,  Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36:1428\u20131439."},{"key":"B79","series-title":"Blood","first-page":"238","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Herrera AF","year":"2019","unstructured":"Herrera AF, Manley T, Sacchi M,  Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study. Blood 2019;134:238."},{"key":"B80","series-title":"Blood","first-page":"427","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani RH","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL,  Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138:427\u2013438."},{"key":"B81","series-title":"J Clin Oncol","first-page":"3733","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand P","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V,  Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016;34:3733\u20133739."},{"key":"B82","series-title":"J Clin Oncol","first-page":"2125","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen R","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA,  Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125\u20132132."},{"key":"B83","series-title":"Lancet Oncol","first-page":"512","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla J","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A,  Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22:512\u2013524."},{"key":"B84","series-title":"J Clin Oncol","first-page":"3109","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz AJ","year":"2021","unstructured":"Moskowitz AJ, Shah G, Schoder H,  Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39:3109\u20133117."},{"key":"B85","series-title":"Blood","first-page":"3605","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei MG","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM,  Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood 2022;139:3605\u20133616."},{"key":"B86","series-title":"J Clin Oncol","first-page":"1479","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie J","year":"2019","unstructured":"Nie J, Wang C, Liu Y,  Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma. J Clin Oncol 2019;37:1479\u20131489."},{"key":"B87","series-title":"Clin Cancer Res","first-page":"2782","article-title":"Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy","volume":"27","author":"Wang C","year":"2021","unstructured":"Wang C, Liu Y, Dong L,  Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy. Clin Cancer Res 2021;27:2782\u20132791."},{"key":"B88","series-title":"J Immunother Cancer","first-page":"e002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu Y","year":"2021","unstructured":"Liu Y, Wang C, Li X,  Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma. J Immunother Cancer 2021;9:e002347."},{"key":"B89","series-title":"Blood","first-page":"1359","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei M","year":"2023","unstructured":"Mei M, Chen L, Godfrey J,  Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood 2023;142:1359\u20131370."},{"key":"B90","series-title":"Hemasphere","first-page":"e70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei M","year":"2025","unstructured":"Mei M, Palmer J, Lee HJ,  Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma. Hemasphere 2025;9:e70126."},{"key":"B91","series-title":"Haematologica","first-page":"2146","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial","volume":"108","author":"Ding K","year":"2023","unstructured":"Ding K, Liu H, Ma J,  Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica 2023;108:2146\u20132154."},{"key":"B92","series-title":"J Clin Oncol","first-page":"1522","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting A","year":"2005","unstructured":"Josting A, Nogova L, Franklin J,  Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522\u20131529."},{"key":"B93","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1100","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine LS","year":"2018","unstructured":"Constine LS, Yahalom J, Ng AK,  The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018;100:1100\u20131118."},{"key":"B94","series-title":"Blood","first-page":"2489","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson BD","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L,  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016;128:2489\u20132496."},{"key":"B95","series-title":"Blood","first-page":"1183","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera AF","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL,  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131:1183\u20131194."},{"key":"B96","series-title":"JAMA Oncol","first-page":"683","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan LJ","year":"2023","unstructured":"Bryan LJ, Casulo C, Allen PB,  Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. JAMA Oncol 2023;9:683\u2013691."},{"key":"B97","series-title":"Lancet Haematol","first-page":"e562","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch RC","year":"2021","unstructured":"Lynch RC, Cassaday RD, Smith SD,  Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study. Lancet Haematol 2021;8:e562\u2013571."},{"key":"B98","series-title":"Ann Oncol","first-page":"iv25","article-title":"Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma","volume":"17","author":"Hertzberg MS","year":"2006","unstructured":"Hertzberg MS, Crombie C, Benson W,  Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma. Ann Oncol 2006;17(Suppl 4):iv25\u201330."},{"key":"B99","series-title":"Arch Intern Med","first-page":"846","article-title":"Neoplastic disease. Treatment with vinblastine. A cooperative study","volume":"116","year":"1965","unstructured":"Neoplastic disease. Treatment with vinblastine. A cooperative study. Arch Intern Med 1965;116:846\u2013852."},{"key":"B100","series-title":"Leuk Lymphoma","first-page":"883","article-title":"Current role of gemcitabine in the treatment of Hodgkin lymphoma","volume":"49","author":"Oki Y","year":"2008","unstructured":"Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 2008;49:883\u2013889."},{"key":"B1","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B2","series-title":"Leukemia","first-page":"1720","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I,  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36:1720\u20131748."},{"key":"B3","series-title":"Blood","first-page":"1229","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo E","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR,  The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229\u20131253."},{"key":"B4","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL,  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: IARC Press; 2017."},{"key":"B5","series-title":"N Engl J Med","first-page":"640","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert A","year":"2010","unstructured":"Engert A, Plutschow A, Eich HT,  Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N Engl J Med 2010;363:640\u2013652."},{"key":"B6","series-title":"N Engl J Med","first-page":"1598","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford J","year":"2015","unstructured":"Radford J, Illidge T, Counsell N,  Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 2015;372:1598\u20131607."},{"key":"B7","series-title":"Blood Adv","first-page":"203","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge TM","year":"2020","unstructured":"Illidge TM, Phillips EH, Counsell N,  Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma. Blood Adv 2020;4:203\u2013206."},{"key":"B8","series-title":"J Clin Oncol","first-page":"1786","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre MPE","year":"2017","unstructured":"Andre MPE, Girinsky T, Federico M,  Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 2017;35:1786\u20131794."},{"key":"B9","series-title":"J Clin Oncol","first-page":"19","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico M","year":"2024","unstructured":"Federico M, Fortpied C, Stepanishyna Y,  Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma. J Clin Oncol 2024;42:19\u201325."},{"key":"B10","series-title":"J Clin Oncol","first-page":"2835","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs M","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C,  Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 2019;37:2835\u20132845."},{"key":"B11","series-title":"Leukemia","first-page":"160","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"38","author":"Fuchs M","year":"2024","unstructured":"Fuchs M, Jacob AS, Kaul H,  Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia 2024;38:160\u2013167."},{"key":"B12","series-title":"Int J Radiat Oncol Biol Phys","first-page":"900","article-title":"Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: relapse analysis of GHSG phase 3 HD16 trial","volume":"111","author":"Baues C","year":"2021","unstructured":"Baues C, Goergen H, Fuchs M,  Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: relapse analysis of GHSG phase 3 HD16 trial. Int J Radiat Oncol Biol Phys 2021;111:900\u2013906."},{"key":"B13","series-title":"Blood","first-page":"1013","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus DJ","year":"2018","unstructured":"Straus DJ, Jung SH, Pitcher B,  CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018;132:1013\u20131021."},{"key":"B14","series-title":"Blood","first-page":"1531","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington SF","year":"2016","unstructured":"Barrington SF, Kirkwood AA, Franceschetto A,  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016;127:1531\u20131538."},{"key":"B15","series-title":"N Engl J Med","first-page":"2419","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson P","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A,  Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 2016;374:2419\u20132429."},{"key":"B16","series-title":"J Clin Oncol","first-page":"13","article-title":"Long-term follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma trial","volume":"42","author":"Luminari S","year":"2024","unstructured":"Luminari S, Fossa A, Trotman J,  Long-term follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma trial. J Clin Oncol 2024;42:13\u201318."},{"key":"B17","series-title":"J Clin Oncol","first-page":"1193","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Brockelmann PJ","year":"2023","unstructured":"Brockelmann PJ, Buhnen I, Meissner J,  Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41:1193\u20131199."},{"key":"B18","series-title":"J Clin Oncol","first-page":"327","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker LM","year":"2023","unstructured":"Fornecker LM, Lazarovici J, Aurer I,  Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol 2023;41:327\u2013335."},{"key":"B19","series-title":"Lancet","first-page":"341","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann P","year":"2024","unstructured":"Borchmann P, Ferdinandus J, Schneider G,  Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 2024;404:341\u2013352."},{"key":"B20","series-title":"Lancet","first-page":"1791","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert A","year":"2012","unstructured":"Engert A, Haverkamp H, Kobe C,  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791\u20131799."},{"key":"B21","series-title":"J Clin Oncol","first-page":"684","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon LI","year":"2013","unstructured":"Gordon LI, Hong F, Fisher RI,  Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684\u2013691."},{"key":"B22","series-title":"N Engl J Med","first-page":"1379","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera AF","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM,  Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med 2024;391:1379\u20131389."},{"key":"B23","series-title":"Blood","first-page":"735","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus DJ","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S,  Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020;135:735\u2013742."},{"key":"B24","series-title":"Lancet Haematol","first-page":"e410","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus DJ","year":"2021","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Connors JM,  Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8:e410\u2013421."},{"key":"B25","series-title":"N Engl J Med","first-page":"310","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell SM","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM,  Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 2022;387:310\u2013320."},{"key":"B26","series-title":"N Engl J Med","first-page":"1478","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos GP","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ,  Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478\u20131484."},{"key":"B27","series-title":"J Clin Oncol","first-page":"1175","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","author":"Merli F","year":"2016","unstructured":"Merli F, Luminari S, Gobbi PG,  Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:1175\u20131181."},{"key":"B28","series-title":"N Engl J Med","first-page":"203","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani S","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A,  ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203\u2013212."},{"key":"B29","series-title":"J Clin Oncol","first-page":"2020","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press OW","year":"2016","unstructured":"Press OW, Li H, Schoder H,  US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 2016;34:2020\u20132027."},{"key":"B30","series-title":"Blood","first-page":"1238","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens DM","year":"2019","unstructured":"Stephens DM, Li H, Schoder H,  Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma. Blood 2019;134:1238\u20131246."},{"key":"B31","series-title":"J Clin Oncol","first-page":"454","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini A","year":"2018","unstructured":"Gallamini A, Tarella C, Viviani S,  Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial. J Clin Oncol 2018;36:454\u2013462."},{"key":"B32","series-title":"Lancet","first-page":"1051","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch DC","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH,  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 1993;341:1051\u20131054."},{"key":"B33","series-title":"Lancet","first-page":"2065","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz N","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M,  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 2002;359:2065\u20132071."},{"key":"B34","series-title":"Br J Haematol","first-page":"645","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz CH","year":"2004","unstructured":"Moskowitz CH, Kewalramani T, Nimer SD,  Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease. Br J Haematol 2004;124:645\u2013652."},{"key":"B35","series-title":"Ann Oncol","first-page":"1312","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi B","year":"2008","unstructured":"Sirohi B, Cunningham D, Powles R,  Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma. Ann Oncol 2008;19:1312\u20131319."},{"key":"B36","series-title":"Bone Marrow Transplant","first-page":"21","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle","volume":"20","author":"Brice P","year":"1997","unstructured":"Brice P, Bouabdallah R, Moreau P,  Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1997;20:21\u201326."},{"key":"B37","series-title":"Blood","first-page":"616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz CH","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD,  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616\u2013623."},{"key":"B38","series-title":"Br J Haematol","first-page":"890","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz CH","year":"2010","unstructured":"Moskowitz CH, Yahalom J, Zelenetz AD,  High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890\u2013897."},{"key":"B39","series-title":"J Clin Oncol","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group","volume":"20","author":"Josting A","year":"2002","unstructured":"Josting A, Franklin J, May M,  New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol 2002;20:221\u2013230."},{"key":"B40","series-title":"Ann Oncol","first-page":"625","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda A","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A,  Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol 2005;16:625\u2013633."},{"key":"B41","series-title":"Biol Blood Marrow Transplant","first-page":"529","article-title":"The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial","volume":"9","author":"Stiff PJ","year":"2003","unstructured":"Stiff PJ, Unger JM, Forman SJ,  The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529\u2013539."},{"key":"B42","series-title":"Biol Blood Marrow Transplant","first-page":"98","article-title":"High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin\u2019s disease: a prognostic model for treatment outcomes","volume":"3","author":"Wheeler C","year":"1997","unstructured":"Wheeler C, Eickhoff C, Elias A,  High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin\u2019s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997;3:98\u2013106."},{"key":"B43","series-title":"Blood","first-page":"801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning SJ","year":"1997","unstructured":"Horning SJ, Chao NJ, Negrin RS,  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801\u2013813."},{"key":"B44","series-title":"Cancer","first-page":"2481","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour E","year":"2007","unstructured":"Jabbour E, Hosing C, Ayers G,  Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma. Cancer 2007;109:2481\u20132489."},{"key":"B45","series-title":"Leuk Lymphoma","first-page":"1668","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova H","year":"2011","unstructured":"Mocikova H, Pytlik R, Markova J,  Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 2011;52:1668\u20131674."},{"key":"B46","series-title":"Biol Blood Marrow Transplant","first-page":"1646","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer JP","year":"2011","unstructured":"Smeltzer JP, Cashen AF, Zhang Q,  Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1646\u20131652."},{"key":"B47","series-title":"Blood","first-page":"1665","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz CH","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD,  Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665\u20131670."},{"key":"B48","series-title":"Ann Oncol","first-page":"167","article-title":"ChlVPP therapy for Hodgkin\u2019s disease: experience of 960 patients","volume":"6","year":"1995","unstructured":"The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin\u2019s disease: experience of 960 patients. Ann Oncol 1995;6:167\u2013172."},{"key":"B49","series-title":"Cancer Invest","first-page":"401","article-title":"Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma","volume":"26","author":"Abali H","year":"2008","unstructured":"Abali H, Ur\u00fcn Y, Oks\u00fczo\u011flu B,  Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26:401\u2013406."},{"key":"B50","series-title":"Ann Oncol","first-page":"593","article-title":"ESHAP is an active regimen for relapsing Hodgkin\u2019s disease","volume":"10","author":"Aparicio J","year":"1999","unstructured":"Aparicio J, Segura A, Garcera S,  ESHAP is an active regimen for relapsing Hodgkin\u2019s disease. Ann Oncol 1999;10:593\u2013595."},{"key":"B51","series-title":"J Clin Oncol","first-page":"396","article-title":"Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease before intensive therapy and autologous bone marrow transplantation","volume":"13","author":"Colwill R","year":"1995","unstructured":"Colwill R, Crump M, Couture F,  Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396\u2013402."},{"key":"B52","series-title":"Ann Oncol","first-page":"1628","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting A","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M,  Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol 2002;13:1628\u20131635."},{"key":"B53","series-title":"Ann Hematol","first-page":"1745","article-title":"ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma","volume":"93","author":"Labrador J","year":"2014","unstructured":"Labrador J, Cabrero-Calvo M, Perez-Lopez E,  ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma. Ann Hematol 2014;93:1745\u20131753."},{"key":"B54","series-title":"Br J Haematol","first-page":"161","article-title":"Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease","volume":"113","author":"Martin A","year":"2001","unstructured":"Martin A, Fernandez-Jimenez MC, Caballero MD,  Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease. Br J Haematol 2001;113:161\u2013171."},{"key":"B55","series-title":"Cancer Chemother Pharmacol","first-page":"161","article-title":"VIM-D salvage chemotherapy in Hodgkin\u2019s disease","volume":"27","author":"Phillips JK","year":"1990","unstructured":"Phillips JK, Spearing RL, Davies JM,  VIM-D salvage chemotherapy in Hodgkin\u2019s disease. Cancer Chemother Pharmacol 1990;27:161\u2013163."},{"key":"B56","series-title":"Ann Oncol","first-page":"609","article-title":"A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas","volume":"6","author":"Rodriguez MA","year":"1995","unstructured":"Rodriguez MA, Cabanillas FC, Hagemeister FB,  A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609\u2013611."},{"key":"B57","series-title":"Ann Oncol","first-page":"1071","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett NL","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL,  Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071\u20131079."},{"key":"B58","series-title":"Haematologica","first-page":"35","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro A","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M,  Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica 2007;92:35\u201341."},{"key":"B59","series-title":"J Clin Oncol","first-page":"3490","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump M","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S,  Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490\u20133496."},{"key":"B60","series-title":"Leuk Lymphoma","first-page":"1523","article-title":"Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium","volume":"51","author":"Gopal AK","year":"2010","unstructured":"Gopal AK, Press OW, Shustov AR,  Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523\u20131529."},{"key":"B61","series-title":"Onco Targets Ther","first-page":"2093","article-title":"Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma","volume":"7","author":"Gutierrez A","year":"2014","unstructured":"Gutierrez A, Rodriguez J, Martinez-Serra J,  Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther 2014;7:2093\u20132100."},{"key":"B62","series-title":"J Clin Oncol","first-page":"456","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz AJ","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA, Perales MA,  Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456\u2013460."},{"key":"B63","series-title":"Blood","first-page":"5119","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger TA","year":"2011","unstructured":"Fehniger TA, Larson S, Trinkaus K,  A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119\u20135125."},{"key":"B64","series-title":"Am J Hematol","first-page":"320","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston PB","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP,  A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320\u2013324."},{"key":"B65","series-title":"J Clin Oncol","first-page":"3293","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro A","year":"2016","unstructured":"Santoro A, Mazza R, Pulsoni A,  Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol 2016;34:3293\u20133299."},{"key":"B66","series-title":"Br J Haematol","first-page":"601","article-title":"Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial","volume":"183","author":"Budde LE","year":"2018","unstructured":"Budde LE, Wu D, Martin DB,  Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial. Br J Haematol 2018;183:601\u2013607."},{"key":"B67","series-title":"J Clin Oncol","first-page":"2183","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes A","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE,  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 2012;30:2183\u20132189."},{"key":"B68","series-title":"Blood","first-page":"1236","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal AK","year":"2015","unstructured":"Gopal AK, Chen R, Smith SE,  Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125:1236\u20131243."},{"key":"B69","series-title":"Leuk Lymphoma","first-page":"3320","article-title":"Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"62","author":"Plattel WJ","year":"2021","unstructured":"Plattel WJ, Bergamasco A, Trinchese F,  Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 2021;62:3320\u20133332."},{"key":"B70","series-title":"Lancet Oncol","first-page":"284","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz AJ","year":"2015","unstructured":"Moskowitz AJ, Schoder H, Yahalom J,  PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16:284\u2013292."},{"key":"B71","series-title":"Blood","first-page":"40","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce AS","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A,  Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018;132:40\u201348."},{"key":"B72","series-title":"Lancet Oncol","first-page":"257","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1\u20132 trial","volume":"19","author":"O\u2019Connor OA","year":"2018","unstructured":"O\u2019Connor OA, Lue JK, Sawas A,  Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1\u20132 trial. Lancet Oncol 2018;19:257\u2013266."},{"key":"B73","series-title":"Biol Blood Marrow Transplant","first-page":"2136","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen R","year":"2015","unstructured":"Chen R, Palmer JM, Martin P,  Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2015;21:2136\u20132140."},{"key":"B74","series-title":"Lancet","first-page":"1853","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz CH","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T,  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853\u20131862."},{"key":"B75","series-title":"Blood","first-page":"2639","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz CH","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A,  Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018;132:2639\u20132642."},{"key":"B76","series-title":"N Engl J Med","first-page":"311","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell SM","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I,  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 2015;372:311\u2013319."},{"key":"B77","series-title":"Lancet Oncol","first-page":"1283","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes A","year":"2016","unstructured":"Younes A, Santoro A, Shipp M,  Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283\u20131294."},{"key":"B78","series-title":"J Clin Oncol","first-page":"1428","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand P","year":"2018","unstructured":"Armand P, Engert A, Younes A,  Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36:1428\u20131439."},{"key":"B79","series-title":"Blood","first-page":"238","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Herrera AF","year":"2019","unstructured":"Herrera AF, Manley T, Sacchi M,  Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study. Blood 2019;134:238."},{"key":"B80","series-title":"Blood","first-page":"427","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani RH","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL,  Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138:427\u2013438."},{"key":"B81","series-title":"J Clin Oncol","first-page":"3733","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand P","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V,  Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016;34:3733\u20133739."},{"key":"B82","series-title":"J Clin Oncol","first-page":"2125","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen R","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA,  Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125\u20132132."},{"key":"B83","series-title":"Lancet Oncol","first-page":"512","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla J","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A,  Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22:512\u2013524."},{"key":"B84","series-title":"J Clin Oncol","first-page":"3109","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz AJ","year":"2021","unstructured":"Moskowitz AJ, Shah G, Schoder H,  Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39:3109\u20133117."},{"key":"B85","series-title":"Blood","first-page":"3605","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei MG","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM,  Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood 2022;139:3605\u20133616."},{"key":"B86","series-title":"J Clin Oncol","first-page":"1479","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie J","year":"2019","unstructured":"Nie J, Wang C, Liu Y,  Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma. J Clin Oncol 2019;37:1479\u20131489."},{"key":"B87","series-title":"Clin Cancer Res","first-page":"2782","article-title":"Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy","volume":"27","author":"Wang C","year":"2021","unstructured":"Wang C, Liu Y, Dong L,  Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy. Clin Cancer Res 2021;27:2782\u20132791."},{"key":"B88","series-title":"J Immunother Cancer","first-page":"e002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu Y","year":"2021","unstructured":"Liu Y, Wang C, Li X,  Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma. J Immunother Cancer 2021;9:e002347."},{"key":"B89","series-title":"Blood","first-page":"1359","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei M","year":"2023","unstructured":"Mei M, Chen L, Godfrey J,  Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood 2023;142:1359\u20131370."},{"key":"B90","series-title":"Hemasphere","first-page":"e70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei M","year":"2025","unstructured":"Mei M, Palmer J, Lee HJ,  Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma. Hemasphere 2025;9:e70126."},{"key":"B91","series-title":"Haematologica","first-page":"2146","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial","volume":"108","author":"Ding K","year":"2023","unstructured":"Ding K, Liu H, Ma J,  Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica 2023;108:2146\u20132154."},{"key":"B92","series-title":"J Clin Oncol","first-page":"1522","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting A","year":"2005","unstructured":"Josting A, Nogova L, Franklin J,  Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522\u20131529."},{"key":"B93","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1100","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine LS","year":"2018","unstructured":"Constine LS, Yahalom J, Ng AK,  The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018;100:1100\u20131118."},{"key":"B94","series-title":"Blood","first-page":"2489","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson BD","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L,  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016;128:2489\u20132496."},{"key":"B95","series-title":"Blood","first-page":"1183","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera AF","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL,  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131:1183\u20131194."},{"key":"B96","series-title":"JAMA Oncol","first-page":"683","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan LJ","year":"2023","unstructured":"Bryan LJ, Casulo C, Allen PB,  Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. JAMA Oncol 2023;9:683\u2013691."},{"key":"B97","series-title":"Lancet Haematol","first-page":"e562","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch RC","year":"2021","unstructured":"Lynch RC, Cassaday RD, Smith SD,  Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study. Lancet Haematol 2021;8:e562\u2013571."},{"key":"B98","series-title":"Ann Oncol","first-page":"iv25","article-title":"Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma","volume":"17","author":"Hertzberg MS","year":"2006","unstructured":"Hertzberg MS, Crombie C, Benson W,  Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma. Ann Oncol 2006;17(Suppl 4):iv25\u201330."},{"key":"B99","series-title":"Arch Intern Med","first-page":"846","article-title":"Neoplastic disease. Treatment with vinblastine. A cooperative study","volume":"116","year":"1965","unstructured":"Neoplastic disease. Treatment with vinblastine. A cooperative study. Arch Intern Med 1965;116:846\u2013852."},{"key":"B100","series-title":"Leuk Lymphoma","first-page":"883","article-title":"Current role of gemcitabine in the treatment of Hodgkin lymphoma","volume":"49","author":"Oki Y","year":"2008","unstructured":"Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 2008;49:883\u2013889."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/2\/article-p41.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/2\/article-p41.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/2\/article-p41.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:46:30Z","timestamp":1770644790000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/2\/article-p41.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":200,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0006","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}